Your browser is no longer supported. Please, upgrade your browser.
Settings
ARPO Aerpio Pharmaceuticals, Inc. daily Stock Chart
ARPO [NASD]
Aerpio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.36 Insider Own33.64% Shs Outstand41.03M Perf Week-2.65%
Market Cap39.57M Forward P/E- EPS next Y-0.54 Insider Trans- Shs Float28.83M Perf Month-4.52%
Income-11.50M PEG- EPS next Q-0.16 Inst Own23.40% Short Float0.43% Perf Quarter-13.90%
Sales20.20M P/S1.96 EPS this Y62.90% Inst Trans-11.86% Short Ratio0.28 Perf Half Y-52.73%
Book/sh1.25 P/B0.77 EPS next Y15.50% ROA-17.70% Target Price3.50 Perf Year-74.29%
Cash/sh- P/C- EPS next 5Y- ROE-20.50% 52W Range0.88 - 4.95 Perf YTD-43.28%
Dividend- P/FCF- EPS past 5Y- ROI-19.00% 52W High-80.59% Beta-
Dividend %- Quick Ratio13.80 Sales past 5Y- Gross Margin- 52W Low9.20% ATR0.05
Employees27 Current Ratio13.80 Sales Q/Q- Oper. Margin- RSI (14)39.08 Volatility4.43% 4.96%
OptionableNo Debt/Eq0.00 EPS Q/Q23.80% Profit Margin-56.90% Rel Volume0.01 Prev Close0.96
ShortableYes LT Debt/Eq0.00 EarningsJun 04 BMO Payout- Avg Volume439.33K Price0.96
Recom2.50 SMA20-5.51% SMA50-6.34% SMA200-56.10% Volume1,203 Change-0.34%
Jul-23-18Initiated Needham Buy $10
Jun-10-19 07:00AM  Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma Business Wire
May-14-19 12:36PM  Wall Street Sees 3 Falling Knives Rebounding Within 52 Weeks GuruFocus.com
May-09-19 07:00AM  Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-02-19 07:00AM  Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects Business Wire
Apr-25-19 07:00AM  Aerpio Pharmaceuticals to Present Data Demonstrating Role of VE-PTP in Conventional Outflow Homeostasis and the Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, as a Treatment for Open-Angle Glaucoma Business Wire
Apr-09-19 09:00AM  Aerpio Pharmaceuticals, Inc. (ARPO) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Apr-05-19 04:05PM  Aerpio Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference Business Wire
Mar-18-19 03:05PM  Aerpio Pharmaceuticals stock plummets after failed trial of diabetic retinopathy treatment MarketWatch -71.29%
01:41PM  Greater Cincinnati pharma firms stock plummets American City Business Journals
07:00AM  Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy Business Wire
Mar-07-19 06:48AM  Aerpio Pharmaceuticals Inc (ARPO) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-05-19 07:00AM  Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Business Wire +5.94%
Feb-26-19 07:00AM  Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 5, 2019 Business Wire +10.27%
Jan-22-19 08:39AM  Aerpio (ARPO) Jumps: Stock Rises 7.8% Zacks +7.88%
Jan-17-19 07:00AM  Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy Business Wire +5.16%
Nov-28-18 04:31PM  Cincinnati stocks soar as Dow Jones posts one of its five biggest gains ever American City Business Journals +6.67%
Nov-14-18 07:30AM  Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-08-18 07:00AM  Aerpio Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference Business Wire
Nov-07-18 07:00AM  Aerpio Reports Third Quarter 2018 Financial Results and Provides Business Update Business Wire
Oct-31-18 07:00AM  Aerpio Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018 Business Wire
Oct-25-18 08:00AM  Aerpio Pharmaceuticals Announces Presentation of Renal Function Data from TIME-2 Study of AKB-9778 in Diabetic Retinopathy Patients at American Society of Nephrology Kidney Week 2018 Business Wire +12.23%
Sep-24-18 07:00AM  Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference Business Wire -5.60%
Aug-30-18 07:00AM  Aerpio Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC Business Wire
Aug-16-18 09:37AM  The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga +8.71%
Aug-14-18 07:00AM  Aerpio Reports Second Quarter 2018 Financial Results and Provides Business Update Business Wire
06:30AM  Aerpio Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 07:00AM  Aerpio Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Tuesday, August 14, 2018 Business Wire -8.48%
Jul-23-18 07:24PM  [$$] Gossamer Bio Bulks Up With $230 Million Series B The Wall Street Journal
Jun-26-18 09:18AM  Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common Stock Business Wire -14.29%
Jun-25-18 04:01PM  Aerpio Pharmaceuticals Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market Business Wire +8.33%
07:00AM  Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease Business Wire
May-31-18 07:00AM  Aerpio Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference Business Wire
May-22-18 08:52AM  Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease Business Wire
May-15-18 06:15PM  Aerpio Pharmaceuticals Announces Nomination of Industry Veteran Cheryl Cohen to Board of Directors Business Wire +8.00%
07:00AM  Aerpio Reports First Quarter 2018 Financial Results and Provides Company Update Business Wire
May-04-18 11:30AM  Aerpio Announces Presentations on Novel Treatments for Glaucoma and Retinal Diseases at ARVO 2018 Annual Meeting Business Wire
Apr-21-18 04:58PM  HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside Benzinga
Mar-20-18 07:10AM  Aerpio Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference Business Wire
Mar-15-18 07:00AM  Aerpio Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference Business Wire
Mar-13-18 07:00AM  Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Business Wire
Mar-07-18 07:00AM  Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, March 13, 2018 Business Wire
Mar-06-18 07:00AM  Aerpio Pharmaceuticals to Present at the Cowen 38th Annual Health Care Conference Business Wire
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2b clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.